ArticleBlood cancer journal2026

Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)-real world experience from the US multiple myeloma immunotherapy consortium.

Cindy Varga et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.